uniQure(US:QURE) TMX Newsfile·2026-02-18 15:06Company Overview - uniQure N.V. is a biotechnology company based in Amsterdam, specializing in gene therapies for rare and severe diseases. Its lead product candidate is AMT-130, which is currently in clinical trials for the treatment of Huntington's disease [2]. Legal Action - A class action lawsuit has been filed against uniQure on behalf of investors who acquired its securities between September 24, 2025, and October 31, 2025. The lawsuit alleges that the company misled investors regarding the design and progress of its pivotal study, leading to inflated market expectations for accelerated approval [1][3]. Stock Performance - Following the announcement of purported positive topline results on September 24, 2025, uniQure's shares surged nearly 250% in a single trading session. However, on November 3, 2025, the company disclosed that the FDA did not accept the Phase I/II study data as sufficient for a Biologics License Application (BLA) submission, resulting in a nearly 50% drop in share price, from $67.69 on October 31, 2025, to $34.29 on November 3, 2025 [3][4].